STOCK TITAN

Lilly Eli & Co - LLY STOCK NEWS

Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.

Overview

Lilly Eli & Co (LLY) is a globally recognized pharmaceutical powerhouse with a heritage that spans nearly a century and a half. Founded in 1876 by Colonel Eli Lilly, the company has consistently transformed scientific research into life‐changing therapies while establishing itself as an authority in pharmaceutical innovation. Operating from its headquarters in Indianapolis, Indiana, Lilly Eli & Co has built a network that spans multiple continents and markets, embodying a commitment to advanced research and manufacturing excellence.

Business Model and Core Competencies

The company generates revenue primarily through the development, production, and global distribution of therapeutic medicines. Its diverse portfolio is underpinned by breakthrough R&D in biotechnology and chemical synthesis. By leveraging strategic investments in research, the company has developed innovative treatments for critical areas such as diabetes, oncology, immunology, and neuroscience. These initiatives not only address significant unmet medical needs but also strengthen its competitive edge in the highly dynamic pharmaceutical sector.

Innovative Research and Development

Lilly Eli & Co excels in turning cutting-edge scientific discoveries into practical, market-ready solutions. The company’s approach integrates state-of-the-art biotechnology, chemical innovation, and genetic medicine – elements that drive its robust R&D engine and pave the way for advances in areas such as targeted cancer therapies, metabolic management, and chronic disease care. Its research programs emphasize both precision medicine and large-scale production, ensuring that new therapies are both effective and accessible.

Global Manufacturing and Supply Chain Excellence

In addition to its research prowess, Lilly Eli & Co has a well-established global manufacturing network. The company has continually expanded its facilities, investing in advanced production capabilities to maintain a reliable supply chain. This commitment to manufacturing excellence helps ensure that high-quality products are delivered efficiently to patients worldwide, reinforcing its reputation as a dependable partner in healthcare.

Market Position and Competitive Edge

As an integrated leader in pharmaceutical technology and therapeutics, Lilly Eli & Co has positioned itself at the intersection of innovation and reliability. The company competes through a blend of long-term research investments, strategic global partnerships, and a relentless focus on improving patient outcomes. Its strong brand legacy and comprehensive portfolio of drugs underline a commitment to scientific excellence and unwavering operational execution.

Commitment to Quality and Patient-Centric Solutions

Quality and trust are central to the company's ethos. With a history of rigorous clinical trials and regulatory approvals, Lilly Eli & Co ensures that its medicines meet the highest standards of safety and efficacy. This patient-centric approach, combined with sustainable manufacturing practices, makes it a reliable source of advanced therapies, fostering long-term trust among healthcare providers and patients alike.

Industry Keywords and Expertise

Industry-specific terms such as pharmaceutical innovation, biotechnology, therapeutics, and advanced manufacturing are integral to understanding the company’s operations. These terms reflect the scientific depth and operational expertise that have allowed Lilly Eli & Co to remain at the forefront of drug discovery and development.

Conclusion

With its rich history, expansive R&D capabilities, and global operational reach, Lilly Eli & Co is a testament to the power of innovation in healthcare. This comprehensive overview highlights not only its diversified business model and advanced research but also its enduring commitment to enhancing patient lives through high-quality, accessible, and effective medicines.

Rhea-AI Summary
Eli Lilly and Company (LLY) announced results from the MONARCH 3 clinical trial, showing a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor. The OS outcomes were not statistically significant. Additional analyses of Verzenio in metastatic and early breast cancer, as well as imlunestrant (oral SERD) in combination with Verzenio, will be presented at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) has announced that Zepbound™ (tirzepatide) injection, indicated for adults with obesity or those who are overweight and have weight-related medical problems, is now available. Following the FDA approval, Zepbound is accessible in six doses through retail and mail-order pharmacies. Zepbound has been added to the National Preferred Formulary for Express Scripts and Cigna Healthcare, with a commercial savings card program available to help eligible individuals access it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends tender offer to acquire POINT Biopharma Global Inc. (NASDAQ: PNT) for $12.50 per share in cash, without interest. The offer has been extended until Dec. 15, 2023, to satisfy the minimum tender condition. Approximately 24.75% of the issued and outstanding shares have been tendered as of Dec. 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
Rhea-AI Summary
Eli Lilly and Company (LLY) announces the FDA approval of Jaypirca (pirtobrutinib) for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Jaypirca is the first and only non-covalent (reversible) BTK inhibitor, offering a new treatment option for patients with CLL or SLL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced plans to open its first-ever Lilly Gateway Labs location in San Diego, Calif. in the first half of 2024. The new location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies. This will be the company's third Gateway Labs location, with additional sites located in San Francisco and Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
-
Rhea-AI Summary
Alexandria Real Estate Equities, Inc. (NYSE: ARE) and Eli Lilly and Company (NYSE: LLY) are collaborating to expand Lilly's innovative Gateway Labs model to the San Diego life science cluster, providing emerging biotechnology companies with mission-critical, flexible laboratories and essential, integrated nontechnical space, opportunities to collaborate with Lilly, and access to capital through Lilly and its venture network. The new Gateway Labs site will be located in Alexandria's University Town Center (UTC) submarket, aiming to accelerate the growth of the San Diego cluster's next generation of leading life science companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
partnership
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) to Invest $2.5 Billion in New High-Tech Manufacturing Site in Germany and $100 Million in Early-Stage Life Sciences Ecosystem
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) extends the expiration of the tender offer to acquire all outstanding shares of POINT Biopharma Global Inc. (NASDAQ: PNT) at $12.50 per share in cash. The offer, previously set to expire on Nov. 16, 2023, has been extended to Dec. 1, 2023, to satisfy the minimum tender condition. Regulatory approvals have been obtained, and approximately 26.45% of the outstanding shares have been tendered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
-
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) obtains NRC Consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license. This follows the completion of Lilly's tender offer to acquire all POINT's common stock for $12.50 per share in cash. The NRC Consent is the final regulatory approval needed for the transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announces participation in the Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D., to join a fireside chat at 3:50 p.m., Eastern time. The live audio webcast will be available on Lilly's Investor website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences

FAQ

What is the current stock price of Lilly Eli & Co (LLY)?

The current stock price of Lilly Eli & Co (LLY) is $813.48 as of March 14, 2025.

What is the market cap of Lilly Eli & Co (LLY)?

The market cap of Lilly Eli & Co (LLY) is approximately 725.8B.

What is the primary focus of Lilly Eli & Co?

Lilly Eli & Co is focused on developing, manufacturing, and globally distributing innovative therapeutic medicines across areas like diabetes, oncology, immunology, and neuroscience.

How does the company generate its revenue?

The company generates revenue through its extensive R&D efforts, production of high-quality medicines, and worldwide sales, supported by a robust manufacturing network and strategic global partnerships.

What sets Lilly Eli & Co apart in the pharmaceutical industry?

Its long history of innovation, combined with cutting-edge research, advanced manufacturing capabilities, and a strong commitment to quality, positions Lilly Eli & Co as a trusted and pioneering leader in healthcare.

How does Lilly Eli & Co ensure the quality and safety of its products?

The company follows rigorous clinical trial protocols and regulatory standards, ensuring that every product meets the highest levels of safety and efficacy before reaching patients around the world.

Where is Lilly Eli & Co headquartered?

Lilly Eli & Co is headquartered in Indianapolis, Indiana, and operates an extensive global network to support its manufacturing and research activities.

What role does research and development play at Lilly Eli & Co?

R&D is central to the company’s business model, driving innovation in drug discovery, advanced biotechnology applications, and the development of novel therapies to address critical health challenges.

How does Lilly Eli & Co contribute to global healthcare?

By providing innovative, high-quality medicines across diverse therapeutic areas and maintaining an efficient global distribution network, the company helps improve patient outcomes and supports health systems worldwide.

What are some key industry keywords associated with the company?

Key terms include pharmaceutical innovation, biotechnology, therapeutics, research and development, advanced manufacturing, and clinical excellence.
Lilly Eli & Co

NYSE:LLY

LLY Rankings

LLY Stock Data

725.80B
946.07M
0.15%
83.27%
0.8%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS